Fanlian Huazhuo Formula:A promising herbal preparation for metabolic liver disease

作     者：Bhupesh Singla 

作者机构：Pharmaceutical SciencesThe University of Tennessee Health Science CenterMemphisTN 38103United States 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文）)

年 卷 期：2024年第30卷第46期

页      面：4964-4968页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Supported by the National Institutes of Health Grants,No.K99HL146954 and No.R00HL146954 the College of Pharmacy Seed Research Grant Program of the University of Tennessee Health Science Center 

主　　题：Metabolic dysfunction-associated steatotic liver disease Fanlian Huazhuo Formula De novo lipogenesis Cell death Adenosine-5’-monophosphate-activated protein kinase alpha Acetyl-CoA carboxylase 

摘      要：The prevalence of metabolic dysfunction-associated steatotic liver disease(MASLD)has increased significantly in recent decades and is projected to increase further due to the rising obesity *** patients are at higher risk of developing advanced liver diseases“cirrhosis and hepatocellular carcinomaas well as liver-or cardiovascular-related *** lipid-lowering therapies failed to reduce the risk of mortality in these ***,there is an urgent need for pharmacotherapies that can control and even reverse this *** Huazhuo Formula(FLHZF)is a combination herbal preparation,and its various individual constituents regulate hepatic lipid metabolism,adipose tissue inflammation,and gut ***,these useful effects,limited information is available on its benefits in diet-induced *** this article,we discuss the research findings recently published about the therapeutic effects of FLHZF in suppressing MASLD development and underlying *** a series of in vitro and in vivo experiments,the authors demonstrated for the first time that FLHZF suppresses MASLD in male mice possibly by inhibiting hepatic de novo lipogenesis pathways and reducing hepatocyte *** study paves the way for future investigations aimed at investigating FLHZF’s role in inhibiting lipogenesis particularly using radioactively-labeled glucose and acetate,and governing hepatocyte mitochondrial function,gut microbiome profile,and its effects in other models of MASLD,and female mice.